CATHERINE HARRINGTON: Open Payments
NPI 1962445627 · MAX MEADOWS, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$491 in 30 payments from 12 companies in 2025. Trend: 2023 $405 · 2024 $582 · 2025 $491
Food & beverage: $491
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $165 |
| Vanda Pharmaceuticals Inc. | 3 | $52 |
| Amgen Inc. | 3 | $46 |
| AstraZeneca Pharmaceuticals LP | 2 | $45 |
| PFIZER INC. | 2 | $39 |
| Dexcom, Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Novo Nordisk Inc | 1 | $25 |
| Lilly USA, LLC | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $19 |
Products named: VRAYLAR, QULIPTA, OTEZLA, FANAPT, AIRSUPRA, Dexcom G6 Transmitter, REXULTI, Ozempic.
Industry payments across VA — which companies pay providers there.
